Hongbo Lu is the founding member of NEXTBio Capital, a newly launched biotech investment firm. Dr. Lu has 20+ years of healthcare investment experience in both public securities and private companies, including her previous tenure as Managing Partner of Vivo Capital, Managing Partner at Lilly Asia Ventures (LAV), and Managing Director at OrbiMed Advisors. Over her investment career, Dr. Lu served on the boards of over 20 healthcare companies, including Turning Point Therapeutics (TPTX, acquired by BMS), Crown Bioscience Inc (6554.TT, acquired by JSR Life Sciences), Avedro (AVDR, acquired by Glaukos), Terns Pharmaceuticals (TERN), BlossomHill Therapeutics Inc, Zenas Biopharma, Createrna, Avistone Pharmaceuticals, and Echosens, among others. Dr. Lu also was extensively involved in the company incubations of ADARx Pharmaceuticals, RiboX Therapeutics, Visirna Inc., Ablaze Pharmaceuticals, Elpiscience, and Ronovo Surgical, and served as a founding director at Inception. Dr. Lu started her Wall Street career as a biotech analyst at Piper Jaffray & Co. and her scientific career in biotech start-ups in the Bay Area. Dr. Lu earned a Ph.D. (Bioengineering) from the University of Washington; an M.B.A. from the Haas School of Business at the University of California, Berkeley; and graduated with honors from Tsinghua University in China.
What is Hongbo Lu's net worth?
The estimated net worth of Hongbo Lu is at least $1.60 million as of September 13th, 2024. Lu owns 58,823 shares of Terns Pharmaceuticals stock worth more than $1,595,868 as of December 5th. This net worth approximation does not reflect any other assets that Lu may own. Learn More about Hongbo Lu's net worth.
How do I contact Hongbo Lu?
Has Hongbo Lu been buying or selling shares of Terns Pharmaceuticals?
Hongbo Lu has not been actively trading shares of Terns Pharmaceuticals during the past quarter. Most recently, on Thursday, September 12th, Hongbo Lu bought 476,190 shares of Terns Pharmaceuticals stock. The stock was acquired at an average cost of $10.50 per share, with a total value of $4,999,995.00. Following the completion of the transaction, the director now directly owns 476,190 shares of the company's stock, valued at $4,999,995. Learn More on Hongbo Lu's trading history.
Who are Terns Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Terns Pharmaceuticals?
In the last year, Terns Pharmaceuticals insiders bought shares 5 times. They purchased a total of 63,764 shares worth more than $297,042.68. In the last year, insiders at the sold shares 9 times. They sold a total of 63,938 shares worth more than $665,822.98. The most recent insider tranaction occured on November, 4th when Director Jill M Quigley sold 24,520 shares worth more than $441,360.00. Insiders at Terns Pharmaceuticals own 1.5% of the company.
Learn More about insider trades at Terns Pharmaceuticals. Information on this page was last updated on 11/4/2025.
